{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:17:56Z","timestamp":1793578676839,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>FLT3-internal tandem duplication measurable residual disease testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clinical standard-of-care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033569","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:02:58Z","timestamp":1780556578000},"page":"910-913","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["ELN-DAVID recommendations for NGS-based\n                    <i>FLT3<\/i>\n                    -ITD MRD testing for patients with acute myeloid leukemia"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-8067","authenticated-orcid":false,"given":"Christopher S.","family":"Hourigan","sequence":"first","affiliation":[{"name":"1Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-9338","authenticated-orcid":false,"given":"Lisanne","family":"Beugelink","sequence":"additional","affiliation":[{"name":"2Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3576","authenticated-orcid":false,"given":"Jad","family":"Othman","sequence":"additional","affiliation":[{"name":"3The University of Sydney, Sydney, Australia"},{"name":"4Royal North Shore Hospital, Sydney, Australia"},{"name":"5King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Gui","sequence":"additional","affiliation":[{"name":"1Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ivey","sequence":"additional","affiliation":[{"name":"6Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"5King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-2048","authenticated-orcid":false,"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[{"name":"7University Hospital, Dresden University of Technology, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[{"name":"8Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-9354","authenticated-orcid":false,"given":"Laura W.","family":"Dillon","sequence":"additional","affiliation":[{"name":"1Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"9Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"10Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-4343","authenticated-orcid":false,"given":"Ing Soo","family":"Tiong","sequence":"additional","affiliation":[{"name":"9Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-2691","authenticated-orcid":false,"given":"Sun","family":"Loo","sequence":"additional","affiliation":[{"name":"6Alfred Hospital, Melbourne, VIC, Australia"},{"name":"10Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"11The Northern Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"12University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5378-4523","authenticated-orcid":false,"given":"Isabell","family":"Arnhardt","sequence":"additional","affiliation":[{"name":"13Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3718-999X","authenticated-orcid":false,"given":"Artur","family":"Kowalik","sequence":"additional","affiliation":[{"name":"14Holy Cross Cancer Center, Kielce, Poland"},{"name":"15Jan Kochanowski University, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-9350","authenticated-orcid":false,"given":"Nicola","family":"Potter","sequence":"additional","affiliation":[{"name":"5King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong","family":"Hwan Kim","sequence":"additional","affiliation":[{"name":"16Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-9546","authenticated-orcid":false,"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[{"name":"17University Hospital of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[{"name":"18University Hospital Center of Lille, University of Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"13Hannover Medical School, Hannover, Germany"},{"name":"19University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J. M.","family":"Valk","sequence":"additional","affiliation":[{"name":"2Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2026081311213076600_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD working party","volume":"147","author":"Cloos","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026081311213076600_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"Jama"},{"issue":"4","key":"2026081311213076600_bib3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026081311213076600_bib4","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2026081311213076600_bib5","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026081311213076600_bib6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"2026081311213076600_bib7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"10388","key":"2026081311213076600_bib8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"23","key":"2026081311213076600_bib9","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1182\/bloodadvances.2024013758","article-title":"Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"Blood Adv"},{"issue":"23","key":"2026081311213076600_bib10","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.2023020301","article-title":"Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG","volume":"142","author":"Loo","year":"2023","journal-title":"Blood"},{"key":"2026081311213076600_bib14","author":"National Comprehensive Cancer Network","year":"2025"},{"issue":"3","key":"2026081311213076600_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/bloodadvances.2025016444","article-title":"FLT3-ITD measurable residual disease from the QuANTUM-First trial","volume":"10","author":"Levis","year":"2025","journal-title":"Blood Adv"},{"issue":"15","key":"2026081311213076600_bib12","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026081311213076600_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2024-201595","article-title":"Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: results of the phase 2 randomized Precog 0905 study in newly diagnosed FLT3 mutated AML","volume":"144","author":"Luger","year":"2024","journal-title":"Blood"},{"key":"2026081311213076600_bib15","author":"Invivoscribe","year":"2025"},{"issue":"10","key":"2026081311213076600_bib16","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41375-023-01994-x","article-title":"FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML","volume":"37","author":"Othman","year":"2023","journal-title":"Leukemia"},{"issue":"10","key":"2026081311213076600_bib17","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"issue":"24","key":"2026081311213076600_bib18","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1182\/bloodadvances.2025017244","article-title":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML","volume":"9","author":"Russell","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"2026081311213076600_bib19","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jtct.2025.01.167","article-title":"Fnih MRD in AML biomarkers consortium: evaluation of methods for detection of FLT3 internal tandem duplication measurable residual disease in acute myeloid leukemia","volume":"31","author":"Dillon","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2026081311213076600_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.21955","article-title":"Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations","volume":"51","author":"Thol","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2026081311213076600_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.16362","article-title":"Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia","volume":"188","author":"Ghannam","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2026081311213076600_bib22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jama.2023.8653","article-title":"DNA sequencing in adults with acute myeloid leukemia to detect residual disease prior to hematopoietic cell transplant-reply","volume":"330","author":"Gui","year":"2023","journal-title":"JAMA"},{"issue":"19","key":"2026081311213076600_bib23","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026081311213076600_bib24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/bloodadvances.2024014490","article-title":"Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML","volume":"9","author":"Vonk","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"2026081311213076600_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41409-025-02757-1","article-title":"Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia","volume":"61","author":"Al-Ali","year":"2026","journal-title":"Bone Marrow Transpl"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/7\/910\/2537512\/blood_bld-2026-033569-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/7\/910\/2537512\/blood_bld-2026-033569-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:21:39Z","timestamp":1786634499000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/7\/910\/568860\/ELN-DAVID-recommendations-for-NGS-based-FLT3-ITD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033569","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,13]]},"published":{"date-parts":[[2026,8,13]]}}}